Promising Nasal Administration Treatment for Non-Active Secondary Progressive MS: Tarun Singhal, MD, MBBS
The director of the PET Imaging Program in Neurologic Diseases at Brigham and Women’s Hospital talked about nasal administration of foralumab that shows promise in treating patients with non-active secondary progressive MS. [WATCH TIME: 5 minutes]
WATCH TIME: 5 minutes
"This approach with the nasal administration of the drug, we believe, actually leads to a modulation of the immune system in such a way that it makes it more regulatory in its nature."
In the current care landscape for multiple sclerosis (MS), the majority of treatments are based mainly on injectable drugs which has reports of low patient compliance. Newer therapies for nasal delivery such as foralumab (Tiziana Life Sciences) are being investigated in MS and may be a potential alternative for patients who may experience swallowing disturbances or prefer non-injectable drugs. According to a study published in the Journal of Neuroimmunology, investigators noted that future research should confirm the superiority of nasal administration of drugs as a potential treatment method in MS for its clinical effectiveness.1
New data from an
These results were presented at the
REFERENCES
1. Duchi S, Ovadia H, Touitou E. Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis. J Neuroimmunol. 2013;258(1-2):32-40. doi:10.1016/j.jneuroim.2013.02.013
2. Singhal T, Zurawski Jm Cicero S, et al. Treatment of PIRA with nasal foralumab dampens microglial activation and stabilizes clinical progression in non-active secondary progressive MS. Presented at: 2024 AAN Annual Meeting; April 13-18; Denver, CO.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Perispinal Etanercept Shows No Efficacy in Treating Chronic Stroke
September 16th 2025